数字乳腺X线摄影、断层合成与对比增强乳腺摄影:筛查检查中平均腺体剂量的个体内比较
本回顾性研究纳入389例乳腺癌高风险女性,在2019年2月至2021年4月期间个体内比较FFDM、DBT、FFDM-DBT联合方案及CEM的平均腺体剂量。每侧乳房中位MGD在FFDM为4.07 mGy、DBT为4.97 mGy、CEM总体为5.87 mGy,CEM高于FFDM或DBT单独使用但差异小,且低于FFDM-DBT联合方案的9.38 mGy。
要点
- 每侧乳房中位MGD:FFDM 4.07 mGy,DBT 4.97 mGy,CEM总体5.87 mGy,FFDM-DBT联合9.38 mGy。
- CEM总体MGD高于FFDM或DBT单独使用,但低于FFDM-DBT联合方案。
- CEM低能1.90 mGy与高能1.90 mGy相加为5.87 mGy,对应有效剂量0.70 mSv。
核心结论
- 在筛查检查的个体内比较研究中,每侧乳房MGD在CEM高于FFDM或DBT单独使用,但差异小,且CEM的MGD低于FFDM-DBT联合方案。
研究设计与样本
- 回顾性研究,纳入389例乳腺癌高风险女性(中位年龄57.4岁),共评估764侧乳房(左383侧、右381侧),为早期前瞻性临床试验参与者在2019年2月至2021年4月期间接受FFDM-DBT联合与CEM筛查。
诊断标准与关键数值
- 每侧乳房(CC与MLO视图合并)中位MGD:FFDM单独4.07 mGy,DBT单独4.97 mGy,FFDM-DBT联合9.38 mGy,CEM低能3.96 mGy,CEM高能1.90 mGy,CEM总体5.87 mGy;对应有效剂量分别为0.49、0.60、1.13、0.48、0.23、0.70 mSv。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Contrast-enhanced mammography (CEM) is growing in clinical use due to its increased sensitivity and specificity compared with full-field digital mammography (FFDM) and/or digital breast tomosynthesis (DBT), particularly in patients with dense breasts. OBJECTIVE. The purpose of this study was to perform an intraindividual comparison of mean glandular dose (MGD) with FFDM, DBT, a combination protocol using both FFDM and DBT (hereafter, combined FFDM-DBT), and CEM in patients undergoing breast cancer screening. METHODS. This retrospective study included 389 women (median age, 57.4 years) with an elevated risk of breast cancer who, as part of participation in an earlier prospective clinical trial, underwent breast cancer screening with combined FFDM-DBT and CEM between February 2019 and April 2021. A total of 764 breasts (383 left, 381 right) were evaluated. One craniocaudal (CC) view and one mediolateral oblique (MLO) view were evaluated per breast for each of FFDM, DBT, and CEM. MGD values were extracted from DICOM metadata. BI-RADS breast density categories were extracted from clinical radiology reports. Data were summarized descriptively, including determination of corresponding effective doses. RESULTS. The breast density category was A in zero patients, B in 44 patients (88 breasts), C in 306 patients (599 breasts), and D in 39 patients (77 breasts). The median MGD per breast (CC and MLO views combined) was 4.07 mGy for FFDM alone, 4.97 mGy for DBT alone, 9.38 mGy for combined FFDM-DBT, 3.96 mGy for low-energy CEM, 1.90 mGy for high-energy CEM, and 5.87 for CEM overall. Corresponding effective dose values were 0.49, 0.60, 1.13, 0.48, 0.23, and 0.70 mSv, respectively. The median MGD for density categories B, C, and D, respectively, was 4.01, 4.22, and 2.70 mGy for FFDM; 5.93, 4.93, and 3.17 mGy for DBT; and 5.90, 6.02, and 4.52 mGy for CEM. CONCLUSION. In this intraindividual comparative study of screening examinations, the MGD per breast was higher for CEM than for FFDM or DBT alone. However, these differences were small, and MGD was lower for CEM than for combined FFDM-DBT. CLINICAL IMPACT. These findings are relevant to ongoing considerations of the role of CEM in breast cancer screening pathways.
引用
- Sanders JW, Pavlicek W, Stefan W, et al. Digital Mammography, Tomosynthesis, and Contrast-Enhanced Mammography: Intraindividual Comparison of Mean Glandular Dose for Screening Examinations. AJR Am J Roentgenol. 2025. PMID: 39813603. doi:10.2214/AJR.24.32150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。